gp1 semaglutide GLP-1-based meds linked to fewer

Novo Nordisks semaglutidemarketed under the names Wegovy and Ozempichave already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly

Sugar replacement recommendations: 130 grams Allulose will equal 100 grams sugar

Our study aims to investigate the impact of GLP-1RA initiation on risks of AF/Aflutter and stroke in patients with T2D treated with levothyroxine, compared to sodium-glucose cotransporter 2 (SGLT2) inhibitors

Completion of the trials main phase is expected in September 2025, and the 52-week extension (in which participants and investigators remain blinded to treatment assignment) will continue to October 2026

Inflammatory bowel diseases (IBD), including Crohns disease (CD) and ulcerative colitis (UC), are chronic, relapsing, intestinal inflammatory disorders with complex and yet unrevealed pathogenesis in which genetic, immunological, and environmental factors play a role